Pacific Biosciences of California, Inc., commonly referred to as PACB, holds a distinct position in the genomics space with its HiFi long-read sequencing technology based on Single-Molecule Real-Time (SMRT) chemistry. This approach delivers highly accurate, detailed genome views that capture structural variants, repeat expansions, and methylation patterns often missed by traditional short-read methods. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The advantage matters more in clinical settings, where combining tests into one assay can speed up diagnoses and cut overall costs. Management has highlighted the Revio system for high-volume work and the Vega system for easier entry; many Vega placements have gone to new customers, pointing to a broader installed base beyond upgrades alone.
The focus now centers on moving from equipment sales to recurring consumables and service revenue, which offers steadier margins. Combined with lower operating costs after restructuring, this supports the goal of reaching cash-flow breakeven by the end of 2027. The main risk stays tied to dependence on research funding and competition from larger sequencing firms.
Several factors could influence sentiment in the quarters ahead. The launch of SparkNex and SPRQ-Nx chemistry stands out; beta data showed notable yield improvements per SMRT Cell, and wider availability should boost consumables usage on both Revio and Vega systems.
Broader clinical and population-scale programs, such as rare-disease work, carrier screening, and national pangenome efforts, offer sustained demand that may turn pilots into larger contracts. Recent regulatory progress, including clinical-grade approvals in China for thalassemia testing, could open additional markets.
Earnings reports will serve as checkpoints on consumables growth and margin trends against 2026 guidance of roughly $165 million to $180 million in revenue and 41% to 44% non-GAAP gross margin.
Analyst views remain positive overall. Eight analysts polled by S&P Global give a consensus “Buy” rating with an average price target near $2.74, spanning $2.00 to $3.00. Recent moves show some variation: Canaccord Genuity kept a Buy at $3.00, Piper Sandler lifted its target to $3.00, UBS cut its target to $2.70 with a Neutral rating, and Barclays held a Sell at a raised $2.00 target. Future changes will likely depend on clinical progress and funding trends.
PACB’s path connects closely to the life-sciences tools cycle and public research budgets. Ongoing questions around NIH funding and academic capital spending have slowed instrument placements, and guidance assumes a subdued academic backdrop. Any recovery in government research support could lift instrument demand, while extended cuts might limit near-term revenue growth.
Higher interest rates have lengthened buying cycles for expensive systems and increased scrutiny on cash-burning companies. On the upside, long-term genomics trends—declining sequencing costs, precision medicine growth, and population-scale initiatives—continue to support the sector. Input-cost swings, such as memory and compute pricing, add another margin consideration the company has noted.
Looking to 2026 and further out, PACB’s results will depend on whether clinical and consumables gains can offset academic pressures. Guidance points to mid-single-digit to low-double-digit revenue growth, supported by a stronger consumables mix and efficiencies from new chemistry. Consensus revenue estimates near $179 million imply about 14% growth, suggesting analysts expect an uptick as the installed base expands.
Over the longer term, the main themes include wider use of HiFi sequencing in clinical diagnostics, scaling of carrier-screening and rare-disease programs, and the economics of population-scale genomics. Cost management, including production insourcing and disciplined expenses, will decide if the company meets its cash-flow breakeven target on time. Competition from larger players and further funding reductions remain the chief risks. Consensus price targets reflect external analyst views only, not this article’s own projection.
I often turn to Tickeron’s Trend Prediction Engine when evaluating stocks like PACB. This AI-powered tool provides forecasts on whether an asset may trend bullish, bearish, or sideways over the coming weeks or months. It helps surface potential breakouts or reversals and offers historical context across many instruments. For investors following PACB, it serves as a useful data-driven complement to fundamental analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The 50-day moving average for PACB moved above the 200-day moving average on October 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACB advanced for three days, in 226 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 109 of 138 cases where PACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The 10-day RSI Indicator for PACB moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 27 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PACB as a result. In 74 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for PACB turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 38 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
PACB moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
PACB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PACB's P/B Ratio (-21.104) is slightly lower than the industry average of (4.142). P/E Ratio (-5.369) is within average values for comparable stocks, (3.291). PACB's Projected Growth (PEG Ratio) (180.110) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.565) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of sequencing system products to help scientists to resolve genetically complex problems
Industry MedicalNursingServices